FIELD: immunology.
SUBSTANCE: options of an antibody or its antigen-binding fragment are proposed, which specifically bind apple 2 domain of human XI clotting factor and inhibit FXI activation. Compositions for the treatment of thromboembolic disorder or disease containing the antibody or antigen-binding fragment are also proposed.
EFFECT: antibody or antigen-binding fragment can be used for the treatment of thromboembolic disorder or disease in a subject, for the inhibition of FXI activation using XIIa (FXIIa) factor in a subject, as well as for the inhibition of blood clotting and associated thrombosis without compromising hemostasis.
46 cl, 10 ex, 5 tbl, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MODIFIED IGG ANTIBODIES WHICH BIND TO A TRANSFORMING GROWTH FACTOR BETA-1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITY | 2016 |
|
RU2728858C2 |
| ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
| NOVEL ANTIBODIES TO BSSL | 2020 |
|
RU2826992C2 |
| ANTIBODIES TO FACTOR XI | 2017 |
|
RU2800719C2 |
| ANTIBODY TO PD-L1, ITS ANTIGEN-BINDING FRAGMENT, AND THEIR PHARMACEUTICAL USE | 2019 |
|
RU2778085C2 |
| ANTIGEN-BINDING PROTEINS AGAINST GITR AND METHODS OF THEIR USE | 2017 |
|
RU2795625C2 |
| Therapeutic antibodies to CD47 | 2016 |
|
RU2748401C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| COMPOSITIONS FOR INHIBITING MASP-2-DEPENDENT COMPLEMENT ACTIVATION | 2017 |
|
RU2725958C2 |
